RESUMO
Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. However, its pharmacologic effects on T-helper type 17 (Th17) cells have not been fully elucidated. Herein, we demonstrate that Tac inhibits Th17 cell differentiation and proliferation, and expression of IL-17 messenger RNA. The proposed mechanism is that Tac inhibits calcineurin and T-cell receptor stimulation-induced cell division. Because Th17 cells participate in allograft rejection, the results of the present study suggest a novel model of immunosuppression effects of Tac. In addition, they provide further implications for the therapeutic immunosuppression effects of Tac on allograft rejection.
Assuntos
Inibidores de Calcineurina , Imunossupressores/farmacologia , Interleucina-17/metabolismo , Linfócitos T Auxiliares-Indutores/efeitos dos fármacos , Tacrolimo/farmacologia , Animais , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/prevenção & controle , Interleucina-17/genética , Camundongos , Camundongos Endogâmicos C57BL , RNA Mensageiro/metabolismo , Linfócitos T Auxiliares-Indutores/imunologiaRESUMO
Brain metastasis from a malignant mixed Mullerian tumor (MMMT) of the uterus is rare. To our knowledge only three similar cases have been reported in the literature. In this report, the authors present the case of a 57-year-old woman with biopsy-proven cerebellar metastasis from a uterine MMMT. One month after complete resection, the mass showed rapid local recurrence. Attention should be paid to the possibility of unusual brain metastasis from a uterine MMMT, which could have an aggressive clinical course.
